New Perspective in VTE Treatment in Acute Medicall


XALIA-LEA provides data on VTE treatment in regions not studied in XALIA Results for the three primary outcomes demonstrated that rivaroxaban is safe and effective in a broad range of patients, supporting the observations from XALIA and the phase III EINSTEIN studies1 Baseline characteristics between treatment groups were more similar in XALIA-LEA than in XALIA (including age and cancer rates)•Increased familiarity with rivaroxaban in clinical practice since the XALIA study may have influenced prescription patterns Major bleeding rates and all-cause mortality were considerably higher in XALIA-LEA compared with XALIA (for the respective rivaroxaban and standard anticoagulation groups) This was possibly due to the higher proportion of patients with PE and known cancer at baseline enrolled in XALIA-LEA

Download attachment
NH619210.pdf - 27.67 KB